PMID- 36225670
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221014
IS  - 2040-6223 (Print)
IS  - 2040-6231 (Electronic)
IS  - 2040-6223 (Linking)
VI  - 13
DP  - 2022
TI  - Efficacy and safety of bisphosphonates on childhood osteoporosis secondary to 
      chronic illness or its treatment: a meta-analysis.
PG  - 20406223221129163
LID - 10.1177/20406223221129163 [doi]
LID - 20406223221129163
AB  - BACKGROUND: Bisphosphonates are a type of medication that prevents the loss of 
      bone density. Secondary childhood osteoporosis reduces bone strength and results 
      in an increased risk of fragility fracture. This meta-analysis aims to explore 
      the efficacy and safety of bisphosphonates on secondary childhood osteoporosis. 
      METHODS: We performed a systematic search of PubMed, Cochrane library, and Web of 
      Science databases up to 31 July 2022 to screen for random clinical trials (RCTs) 
      on bisphosphonate treatment for childhood secondary osteoporosis. Data from 
      selected studies, mainly changes in lumbar spine (LS) bone mineral density (BMD), 
      changes in LS BMD Z-scores, fracture events, and adverse events (AEs), were 
      extracted and analyzed. RESULTS: Nine RCTs (n = 429 in total) were included in 
      our meta-analysis. The meta-analysis indicated that bisphosphonates improved the 
      changes in LS BMD [mean difference (MD) = 0.04, 95% confidence intervals 
      (CIs) = 0.01-0.07, p < 0.01] and LS BMD Z-scores [MD = 0.52, 95% CI = 0.23-0.81, 
      p < 0.01]. Use of bisphosphonates did not increase the risk of AEs [odds ratio 
      (OR) = 1.61, 95% CI = 0.87-2.99, p = 0.13]. Subgroup analysis showed that routes 
      of administration, but not causes of secondary osteoporosis, might influence the 
      efficacy of bisphosphonates. IV bisphosphonates close to significantly improved 
      the incidence of fracture (OR = 0.34, 95% CI: 0.11-1.08, p = 0.07). CONCLUSIONS: 
      The use of bisphosphonates improves LS BMD without increasing AE rates, which 
      supports the clinical use of bisphosphonates in secondary childhood osteoporosis. 
      Further large RCTs are still warranted, especially for their long-term effects on 
      fracture rates.
CI  - (c) The Author(s), 2022.
FAU - Zhao, Huawei
AU  - Zhao H
AD  - Department of Pharmacy, The Children's Hospital, Zhejiang University School of 
      Medicine and National Clinical Research Center for Child Health, Hangzhou, China.
FAU - Ding, Yunfei
AU  - Ding Y
AD  - Laboratory of Rheumatology & Institute of TCM Clinical Basic Medicine, College of 
      Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, China.
FAU - Yang, Jufei
AU  - Yang J
AD  - Department of Pharmacy, The Children's Hospital, Zhejiang University School of 
      Medicine and National Clinical Research Center for Child Health, Hangzhou, China.
FAU - Luo, Yijun
AU  - Luo Y
AD  - Laboratory of Rheumatology & Institute of TCM Clinical Basic Medicine, College of 
      Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, China.
FAU - Xu, Zhenghao
AU  - Xu Z
AUID- ORCID: 0000-0003-0033-525X
AD  - Laboratory of Rheumatology & Institute of TCM Clinical Basic Medicine, College of 
      Basic Medical Science, Zhejiang Chinese Medical University, No. 548 Binwen Road, 
      Hangzhou 310053, Zhejiang, China.
AD  - Laboratory of Rheumatology & Institute of TCM Clinical Basic Medicine, College of 
      Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, China.
FAU - Miao, Jing
AU  - Miao J
AD  - Department of Pharmacy, The Children's Hospital, Zhejiang University School of 
      Medicine and National Clinical Research Center for Child Health, Hangzhou 310052, 
      Zhejiang, China.
AD  - Department of Pharmacy, The Children's Hospital, Zhejiang University School of 
      Medicine and National Clinical Research Center for Child Health, Hangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20221006
PL  - United States
TA  - Ther Adv Chronic Dis
JT  - Therapeutic advances in chronic disease
JID - 101532140
PMC - PMC9549182
OTO - NOTNLM
OT  - bisphosphonate
OT  - bone mineral density
OT  - children
OT  - secondary osteoporosis
COIS- The authors declared no potential conflicts of interest with respect to the 
      research, authorship, and/or publication of this article.
EDAT- 2022/10/14 06:00
MHDA- 2022/10/14 06:01
PMCR- 2022/10/06
CRDT- 2022/10/13 02:35
PHST- 2022/02/23 00:00 [received]
PHST- 2022/09/07 00:00 [accepted]
PHST- 2022/10/13 02:35 [entrez]
PHST- 2022/10/14 06:00 [pubmed]
PHST- 2022/10/14 06:01 [medline]
PHST- 2022/10/06 00:00 [pmc-release]
AID - 10.1177_20406223221129163 [pii]
AID - 10.1177/20406223221129163 [doi]
PST - epublish
SO  - Ther Adv Chronic Dis. 2022 Oct 6;13:20406223221129163. doi: 
      10.1177/20406223221129163. eCollection 2022.